Sign inJoin waitlistJoin the waitlist

AC

Andrea Cercek

Co-Director, Center for Young Onset Colorectal and Gastrointestinal Cancers · New York Presbyterian Hospital

Credentials: · · · ·

History

Center for Young Onset Colorectal and Gastrointestinal Cancers · New York Presbyterian Hospital
Present
New York Presbyterian Hospital
Present
Colorectal Cancer Section · New York Presbyterian Hospital
Present

Hematology and Medical Oncology
Memorial Sloan Kettering Cancer Center
2007–2010
Internal Medicine
New York Presbyterian Hospital
2004–2007
New York Medical College
2000–2004

Research

Colorectal cancer statistics, 2020
Current Anthropology · 2020 · 3,962 citations
Colorectal cancer statistics, 2023
Current Anthropology · 2023 · 2,982 citations
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Nature Medicine · 2017 · 2,750 citations

LS
Leonard Saltz
70 papers
NK
Nancy Kemeny
66 papers
MW
Martin Weiser
59 papers
MD
Michael D'Angelica
59 papers
WJ
William Jarnagin
58 papers
RY
Rona Yaeger
57 papers · 1 as a fellow
JG
Julio Garcia-Aguilar
56 papers · 14 as a fellow
GN
Garrett Nash
53 papers
JS
Jinru Shia
53 papers
PK
Peter Kingham
48 papers
Philip Paty
48 papers
Jesse Smith
41 papers

Grants

Neoadjuvant Tucatinib Plus Trastuzumab in HER2-Amplified Locally Advanced Rectal Cancer
National Cancer Institute · R01
Contact PI · $1.2M · Sloan-Kettering Inst Can Research
2024–2029
Dose-Response of Aerobic Training During Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer
National Cancer Institute · U01
PI · $4.9M · Sloan-Kettering Inst Can Research
2022–2027
Improving Outcome in Patients with Advanced Intrahepatic Cholangiocarcinoma: A Randomized Phase II Study of Gemcitabine and Oxaliplatin With or Without Regional Floxuridine (FUDR)
National Cancer Institute · U01
PI · $3.3M · Sloan-Kettering Inst Can Research
2020–2025
Neoadjuvant PD-1 Blockade in Mismatch Repair Deficient Rectal Cancer
National Cancer Institute · R21
Contact PI · $451K · Sloan-Kettering Inst Can Research
2021–2024

Clinical trials

A Study of Botensilimab and Balstilimab for Rectal Adenocarcinoma
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2025–2028
A Study of Tucatinib and Trastuzumab in People With Rectal Cancer
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2022–2030
A Study of the Possible Effects of Medication on Young Onset Colorectal Cancer (YOCRC)
Principal investigator · Active not recruiting
Memorial Sloan Kettering Cancer Center
2022–2027
Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery
Principal investigator · Recruiting · Phase 2
Memorial Sloan Kettering Cancer Center
2021–2027